Radical Mastectomy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Radical mastectomy is a major oncological surgical procedure that removes the entire breast, including all overlying skin, the nipple-areola complex, both pectoralis major and pectoralis minor muscles, and all three levels of axillary lymph nodes (Level I, II, and III) in a single en-bloc resection. First described by William Halsted in 1894 and standardised through his landmark 1907 publication in Annals of Surgery, the Halsted radical mastectomy became the defining oncological procedure of the 20th century and dramatically reduced rates of local cancer recurrence in an era before modern adjuvant therapy.

Today, true radical mastectomy is largely of historical significance. Modern breast cancer surgery has evolved toward organ-preserving techniques: modified radical mastectomy — which preserves the pectoral muscles — is now preferred for most patients requiring mastectomy, and breast-conserving surgery (lumpectomy) combined with radiotherapy is the standard of care for eligible early-stage tumours. Classical radical mastectomy is reserved for the small subset of advanced or recurrent breast cancers where tumour directly invades the pectoralis major muscle, making muscle-preserving surgery oncologically inadequate.

Understanding radical mastectomy remains clinically important as a reference standard against which modified techniques are evaluated, and because it remains the appropriate intervention for a small but important group of patients with locally advanced disease.

Radical mastectomy is indicated for a narrow set of clinical circumstances in which the pectoralis major or minor muscles are directly invaded by breast cancer, making organ-preserving or muscle-preserving surgery oncologically unsafe.

Primary indications include: (1) Locally advanced breast cancer (T4b disease) with direct tumour extension into the chest wall or pectoral muscles confirmed on imaging or core biopsy; (2) Inflammatory breast cancer that has not responded adequately to neo-adjuvant chemotherapy and shows residual chest wall involvement at the time of surgery; (3) Local recurrence of breast cancer after prior breast-conserving surgery or modified radical mastectomy in which the recurrence involves the pectoral musculature.

Before surgery is considered, all patients with locally advanced breast cancer receive neo-adjuvant (pre-operative) chemotherapy and often targeted therapy (for HER2-positive or hormone receptor-positive disease), aiming to downstage the tumour and permit less extensive surgery. Radical mastectomy is thus truly a last-resort operation reserved for cases where neo-adjuvant therapy has failed to separate the tumour from the chest wall or where the pectoral muscles are directly involved at staging.

Contraindications include metastatic disease beyond regional lymph nodes (though radical mastectomy may still be performed for palliation in selected cases of fungating tumour), severe cardiac or respiratory comorbidity precluding general anaesthesia, and patient preference against surgery after full multidisciplinary team discussion of alternatives.

Radical mastectomy is performed under general anaesthesia with the patient positioned supine, ipsilateral arm extended on an arm board at 90 degrees. A prophylactic broad-spectrum antibiotic is administered at induction.

Surgical steps:

1. **Incision design:** An elliptical incision is marked encompassing the entire breast, nipple-areola complex, and any overlying skin involvement, with at least 1 cm clear margins. The incision extends to allow adequate axillary access.

1. **Skin flap elevation:** Superior and inferior skin flaps are raised in the plane immediately deep to the dermis, extending to the clavicle superiorly, the midline medially, the anterior axillary line laterally, and the costal margin inferiorly.

1. **Pectoralis major detachment:** The pectoralis major muscle is detached from its sternal and costal origins, then divided at its humeral insertion, removing it with the specimen.

1. **Pectoralis minor removal:** The pectoralis minor muscle is divided at its coracoid process insertion and rib origins, exposing the axillary contents.

1. **Axillary dissection:** All three levels of axillary lymph nodes (Level I — lateral to pectoralis minor; Level II — behind pectoralis minor; Level III — medial to pectoralis minor) are dissected, preserving the long thoracic nerve (to serratus anterior) and thoracodorsal nerve (to latissimus dorsi) where oncologically feasible.

1. **Haemostasis and closure:** Meticulous haemostasis is achieved. Two closed-suction drains are placed — one in the axilla, one under the chest flap. The skin is closed in layers, often with a split-thickness skin graft if skin closure is insufficient.

1. **Specimen handling:** The en-bloc specimen is orientated and sent fresh for histopathological assessment of margins, nodal staging, and receptor status.

Radical mastectomy provides maximal local disease control in patients with chest wall-invasive breast cancer where less extensive surgery would leave behind tumour-involved muscle.

Local recurrence: In appropriately selected patients with T4 disease and pectoral muscle involvement, radical mastectomy followed by adjuvant radiotherapy achieves local recurrence rates of under 10–15% at 5 years, compared with substantially higher recurrence when surgery leaves positive margins at the chest wall.

Survival: Overall 5-year survival for locally advanced breast cancer managed with neo-adjuvant chemotherapy, radical surgery, and adjuvant radiotherapy has improved dramatically to 50–70% in modern series, reflecting advances in systemic therapy rather than surgical technique.

Comparison with modified radical mastectomy: Randomised trials including the landmark Fisher NSABP B-06 trial established that for most breast cancers, modified radical mastectomy achieves equivalent cancer control to radical mastectomy, with superior functional outcomes from pectoral muscle preservation. Radical mastectomy therefore does not confer additional survival benefit over modified radical mastectomy except in the specific circumstance of direct pectoral muscle invasion.

Physiotherapy outcomes: With early post-operative shoulder physiotherapy and lymphoedema management, most patients recover meaningful shoulder function within 6–12 months of surgery. Modern lymphoedema programmes using manual drainage, compression, and exercise achieve significant quality-of-life improvements compared with historical outcomes.

Radical mastectomy carries a higher morbidity profile than modified radical mastectomy or breast-conserving surgery due to its greater tissue removal and the obligatory sacrifice of pectoral muscles and complete axillary contents.

Early complications: - Wound haematoma requiring surgical drainage (3–8%) - Seroma formation under the chest flap (30–60% — drained percutaneously) - Surgical site infection (5–10%) - Skin flap necrosis requiring re-grafting in extensive resections (5–15%) - Haemorrhage requiring return to theatre (under 2%)

Neurological complications: - Long thoracic nerve injury causing winged scapula (serratus anterior palsy) — under 5% in experienced hands - Thoracodorsal nerve injury causing latissimus dorsi weakness — under 3% - Intercostobrachial nerve division causing medial arm numbness — very common, near-universal - Brachial plexus injury — rare (under 1%) but serious

Late complications: - Lymphoedema of the ipsilateral arm: occurs in 20–40% after complete Level I–III axillary dissection, compared with 5–15% after sentinel node biopsy alone. Risk is significantly increased if post-operative axillary radiotherapy is also delivered (up to 40–60%) - Shoulder stiffness and restricted abduction from pectoral muscle loss and axillary scarring - Phantom breast pain and post-mastectomy pain syndrome (chronic neuropathic pain) in 20–30% of patients - Chest wall skin flap complications and scar contracture requiring physiotherapy

Recovery from radical mastectomy requires a structured multi-disciplinary programme covering wound care, physiotherapy, lymphoedema prevention, and psychological support.

Immediate post-operative period (Days 0–14): Hospital stay is typically 3–5 days. Closed-suction drains remain in place until output falls below 30 mL per 24 hours — usually 7–14 days. Surgical drains are logged and patients taught drain care before discharge. The wound is inspected at 10–14 days and sutures or staples removed. Intravenous then oral analgesics manage pain, which is typically well-controlled despite the extent of surgery.

Early rehabilitation (Weeks 2–6): Passive shoulder pendulum exercises begin within 48 hours of surgery to prevent frozen shoulder from axillary scarring and pectoral muscle absence. Active shoulder range-of-motion exercises advance progressively over 6 weeks, guided by a specialist physiotherapist. Driving and lifting restrictions apply for 4–6 weeks depending on the wound and arm function.

Adjuvant therapy: Post-operative radiotherapy to the chest wall and regional lymphatics is standard for locally advanced disease and typically begins 6–8 weeks post-operatively once the wound has healed. Adjuvant chemotherapy and targeted therapy are coordinated with the oncology team.

Long-term lymphoedema care: Lifelong lymphoedema surveillance is essential. All patients are educated about early warning signs (arm swelling, heaviness, tightness) and given written instructions on skin care, infection prevention, and when to seek urgent review. Compression garments, manual lymphatic drainage, and specialist lymphoedema physiotherapy services are available through most comprehensive cancer centres.